Discontinued — last reported Q3 '19

Other Income & Expense

Sublease Income

Vertex Pharmaceuticals Sublease Income remained flat by 0.0% to $50.00K in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 87.5%, from $400.00K to $50.00K. Over 2 years (FY 2023 to FY 2025), Sublease Income shows a downward trend with a -72.8% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.

Analysis

StatementIncome Statement
SectionOther Income & Expense
CategoryProfitability
SignalHigher is better
VolatilityModerate
First reportedQ1 2019
Last reportedQ3 2019

How to read this metric

Higher sublease income indicates effective management of excess capacity, reducing the net burden of fixed lease costs.

Detailed definition

Revenue generated by leasing out excess office space or equipment that the company currently holds under a primary lease...

Peer comparison

Commonly found in the 'other income' or 'operating expense' offsets for companies with large real estate footprints.

Metric ID: is_ms_sublease_income

Historical Data

3 years
 FY'23FY'24FY'25
Value$2.70M$1.60M$200.00K
YoY Change—-40.7%-87.5%
Range$200.00K – $2.70M
CAGR-72.8%
Avg YoY Growth-64.1%
Median YoY Growth-64.1%
Current Streak2+ years decline

Frequently Asked Questions

What is Vertex Pharmaceuticals's sublease income?
Vertex Pharmaceuticals (VRTX) reported sublease income of $50.00K in Q4 2025.
How has Vertex Pharmaceuticals's sublease income changed year-over-year?
Vertex Pharmaceuticals's sublease income decreased by 87.5% year-over-year, from $400.00K to $50.00K.
What is the long-term trend for Vertex Pharmaceuticals's sublease income?
Over 2 years (2023 to 2025), Vertex Pharmaceuticals's sublease income has grown at a -72.8% compound annual growth rate (CAGR), from $2.70M to $200.00K.
What does sublease income mean?
Income earned by renting out unused leased space or assets to third parties.